Abstract:Importance Available antipsychotic medications are predominantly used to treat positive symptoms, such as hallucinations and delusions, in patients with first-episode psychosis (FEP). However, treating negative and cognitive symptoms, which are closely related to functional outcomes, remains a challenge. Objective To explore the cognitive characteristics of patients with negative symptom–dominant (NSD) psychosis. Design, Setting, and Participants This large-scale cross-sectional study of patients with FEP was led by the Shanghai Mental Health Center in China from 2016 to 2021, with participants recruited from 10 psychiatric tertiary hospitals. A comprehensive cognitive assessment was performed among 788 patients with FEP who were drug-naive. Symptom profiles were determined using the Positive and Negative Symptoms Scale (PANSS), and NSD was defined as a PANSS score for negative symptoms higher than that for positive and general symptoms. Positive symptom–dominant (PSD) and general symptom–dominant (GSD) psychosis were defined similarly. Data were analyzed in 2023. Exposure Psychotic symptoms were categorized into 3 groups: NSD, PSD, and GSD. Main Outcomes and Measures Neurocognitive performance, assessed using the Chinese version of the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery. Results This study included 788 individuals with FEP (median age, 22 [IQR, 17-28] years; 399 men [50.6%]). Patients with NSD exhibited more-pronounced cognitive impairment than did those with PSD or GSD. Specifically, cognitive differences between the NSD and PSD group, as well as between the NSD and GSD group, were most notable in the processing speed and attention domains (Trail Making [ F = 4.410; P = .01], Symbol Coding [ F = 4.957; P = .007], Verbal Learning [ F = 3.198; P = .04], and Continuous Performance [ F = 3.057; P = .05]). Patients with PSD and GSD showed no significant cognitive differences. Cognitive impairment was positively associated with the severity of negative symptoms. Most of the cognitive function tests used were able to differentiate patients with NSD from those with PSD and GSD, with significant differences observed across a range of tests, from Brief Visuospatial Memory Test–Revised ( χ2 = 3.968; P = .05) to Brief Assessment of Cognition in Schizophrenia symbol coding ( χ2 = 9.765; P = .002). Conclusions and Relevance The findings of this cross-sectional study of patients with FEP suggest the presence of a clinical subtype characterized by a predominance of negative symptoms and cognitive impairment.

Attenuated Niacin Response is Associated with a Subtype of First-Episode Drug-Naïve Psychosis Characterized As Serious Negative Symptoms

Replication of the Abnormal Niacin Response in First Episode Psychosis Measured Using Laser Doppler Flowmeter

Identification of Adolescent Patients with Depression Via Assessment of the Niacin Skin Flushing Response.

Association of Attenuated Niacin Response with Inflammatory Imbalance and Prediction of Conversion to Psychosis from Clinical High-risk Stage

A potential objective marker in first-episode schizophrenia based on abnormal niacin response

Attenuated niacin-induced skin flush response in individuals with clinical high risk for psychosis

Niacin Skin Sensitivity Is Increased in Adolescents at Ultra-High Risk for Psychosis

Niacin sensitivity and cognitive functions in first episode schizophrenia

N-acetylaspartate reduction in the medial prefrontal cortex following 8 weeks of risperidone treatment in first-episode drug-naïve schizophrenia patients.

Attenuated and delayed niacin skin flushing in schizophrenia and affective disorders: A potential clinical auxiliary diagnostic marker

Cognitive Impairments in Drug-Naive Patients with First-Episode Negative Symptom-Dominant Psychosis

Membrane fatty acids, niacin flushing and clinical parameters

Attenuated Niacin Skin Flushing Response in Children and Adolescents with Mental Disorders: A Transdiagnostic Early Warning Marker

Identification of the Niacin-Blunted Subgroup of Schizophrenia Patients from Mood Disorders and Healthy Individuals in Chinese Population.

[Test for abnormal niacin response syndrome in schizophrenia: reclaiming the oral route]

Altered HCAR3 Expression May Underlying the Blunted Niacin Responses of the Psychiatric Disorders and the Risk of Schizophrenia.

Altered neutrophil-to-lymphocyte ratio in patients with non-affective first episode psychosis and its relationship with symptom severity and cognitive impairment

Altered Antioxidant Defenses in Drug-Naive First Episode Patients with Schizophrenia Are Associated with Poor Treatment Response to Risperidone: 12-Week Results from a Prospective Longitudinal Study

Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode Psychosis

Cognitive Impairment in First-Episode Negative Symptom–Dominant Psychosis

Antipsychotic Drugs Increase Neuregulin1β1 Serum Levels in First-Episode Drug-Naïve Patients and Chronic Schizophrenia with Suggestions for Improving the Treatment of Psychotic Symptoms